Salvage mFOLFOX in BTC After Failure of Gemcitabine
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.
Unresectable Biliary Tract Cancer
DRUG: 5-fluorouracil, leucovorin, oxaliplatin
Response rate, Clinically assessed every cycle (2weeks) and radiologically assessed every 3 cycles (6 weeks) with CT scan, 1 year
To evaluate the safety, Clinically assessed every cycle (2weeks), 1 year|To estimate the time to progression, 1 year|To estimate overall survival, 1 year
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.